Glycosmedia

Diabetes News Service

Privacy & Cookies: This site uses cookies. By continuing to use this website, you agree to their use.
To find out more, including how to control cookies, see here: Cookies Policy
  • News
  • Archive
  • Categories & Tags
  • Journal Watch
  • Updates
  • Education
  • Reviews
  • About us ▼
    • About Glycosmedia
    • Editorial Team
    • Frequently asked questions
    • Comments
    • Press Releases
    • Disclaimer
  • Subscribe
  • Contact

Statin therapies have been in the news over the past few months with the predictable polarisation of views

April 10th 2014

The National Institute for Health and Care Excellence (NICE) have issued a draft full guideline (over 270 pages in length) on lipid modification which, for patients with type 2 diabetes, would replace the current recommendations (REF 1). It recommends the UKPDS tool to assess CV risk and offer of ‘high-intensity statin treatment’ for primary prevention of CVD in people who have a 10% or greater 10-year risk. This is in contrast to the previous advice in NICE CG 66 which suggested a risk cut-off of 20% and use of simvastatin 40mg OD (now classed as ‘medium-intensity’).

The response of the Faculty of Public Health and the RCGPs was that there was the prospect of both over-treatment and over-medicalisation of hypercholesterolaemia. The former is supported by consistent data suggesting that development of type 2 diabetes is more common and control is worse in people receiving statins (2), whilst the latter might explain a report that statin-treated individuals consume more calories (presumably allowing for their medication to compensate) (3). The BMA view was that lowering the baseline risk for treatment would simply overwhelm already exhausted general practitioners (4). They were presumably not reassured by a publication which suggested that statin side-effects had been over-emphasised and were largely down to patients having been told about them (so, consultation times could be reduced by not having to mention muscle pains) (5). Apart from being difficult to believe, this paper was also unusual in that it was criticized by one of its own authors within days of publication (6).

Possibly of most interest, the Americans are changing their guidelines regarding statin therapy (7). For primary prevention (CVD risk >7.5% over 10 years) in type 2 diabetes and where the LDL-cholesterol is 1.8-5.0mmol/L, the recommendation is for introduction of a moderate-intensity statin. The big change, however, is that there is no longer a target to be achieved. This ‘fire-and-forget’ strategy could even reduce primary care workload.

Professor Steve Bain
1 http://guidance.nice.org.uk/CG/WaveR/123
2 http://www.dmsjournal.com/content/6/1/53
3 http://www.redorbit.com/news/health/1113131636/statin-use-is-no-free-ride-042814/
4 http://www.pulsetoday.co.uk/sign-in?rtn=clinical/therapy-areas/cardiovascular/nice-statins-plan-is-unsustainable-for-gps-says-bma-official-response/20006360.article#.U19GPqCTvFI
5 http://www.nhs.uk/news/2014/03March/Pages/Statins-side-effects-are-minimal-study-argues.aspx
6 http://www.badscience.net/2014/03/statins-have-no-side-effects-what-our-study-really-found-its-fixable-flaws-and-why-trials-transparency-matters-again/
7 http://circ.ahajournals.org/content/early/2013/11/11/01.cir.0000437738.63853.7a

Categories: Updates

Diabetes Updates Archive

calendar-iconDiabetes Updates Archive ››

Subscribe

subscribe-iconFREE weekly updates by email Please CLICK HERE

Platinum Sponsors

Boehringer Ingelheim Lilly

Gold Sponsors

AstraZenecaNapp DiabetesNovo NordiskSanofi Diabetes

Silver Sponsors

Abbott Diabetes CareAmgenWelsh Endocrinology and Diabetes Society (WEDS)

FUNDING NOTICE

The Glycosmedia website and newsletter has been made possible with funding support from our sponsors. None of our sponsors have control over the content of the website, newsletter, apps, Twitter feed or RSS newsfeed.

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Advertisers

CRC Press

The organisations advertising in this section do not have any input into, or editorial control over the content of this website.

Join us on Facebook

Join us on Facebook

Please share Glycosmedia:

Follow us on Twitter

My Tweets

mobileGlycosmedia is also available as an App:

For iPhone and iPad | For Android devices


Sponsorship and Advertising

For information about sponsorship and advertising please contact our editor-in-chief Jim Young jim@glycosmedia.com

Copyright © 2021 Glycosmedia Partnership